GMAB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GM

Mkt Cap

$22.75B

Volume

1.91M

Next Earnings

November 5th

Loading chart

GM

GMABGenmab A/S ADS

GMAB

Pay with—

Available Balance0.00

GM

Mkt Cap

$23.26B

Volume

1.91M

Next Earnings

November 5th

Chart Earnings News About Insider Filings

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCLAbbVie and Genmab announced positive phase III EPCORE DLBCL-2 study results showing that epcoritamab combined with R-CHOP significantly improved progression-free survival compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients, reducing disease progression or death risk by 51%. The combination was well tolerated with a safety profile consistent with prior reports.Zacks Investment Research · Oct 6, 2026

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 6, 2026

Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields SurgeThe Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.The Motley Fool · Oct 5, 2026

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaGenmab and AbbVie announced positive Phase 3 trial results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The combination demonstrated a statistically significant 51% reduction in disease progression or death risk compared to R-CHOP alone, with a favorable safety profile. This marks the first Phase 3 study of a bispecific antibody combination to show significant improvement in progression-free survival in frontline DLBCL treatment.GlobeNewswire Inc. · Oct 5, 2026

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian CancerGenmab announced Phase 2 results for Rina-S (rinatabart sesutecan) in platinum-resistant ovarian cancer, demonstrating a 45.9% objective response rate with a median duration of response of 12.1 months and median progression-free survival of 9.5 months. The drug showed antitumor activity regardless of folate receptor alpha expression levels, with manageable tolerability. The company is advancing four Phase 3 trials across multiple gynecologic cancers.GlobeNewswire Inc. · Oct 3, 2026

Major Shareholder AnnouncementDarwin Global Management Limited has disclosed a significant shareholding in Genmab A/S, controlling 3,188,361 shares and ADRs representing 5.11% of voting rights as of September 28, 2026. The announcement was made under Danish Capital Markets Act requirements.GlobeNewswire Inc. · Oct 2, 2026

Grant of Restricted Stock Units and Warrants to Employees in GenmabGenmab A/S announced the grant of 13,794 restricted stock units and 13,331 warrants to employees. The RSUs have a fair value of DKK 2,268 per unit and will vest after three years, while warrants have an exercise price of DKK 2,268 with a Black-Scholes fair value of DKK 781.96, vesting in three years and expiring after seven years.GlobeNewswire Inc. · Sep 24, 2026

Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS InsiderThe global monoclonal antibodies market is projected to grow from USD 280.15 billion in 2025 to USD 791.28 billion by 2035, driven by increasing demand for targeted therapies in oncology, autoimmune disorders, and chronic diseases. North America leads with 41% market share, while Asia-Pacific shows the fastest growth at 12.32% CAGR. Key innovations include bispecific antibodies and antibody-drug conjugates, with humanized antibodies emerging as the fastest-growing segment.GlobeNewswire Inc. · Sep 9, 2026

Capital Increase in Genmab as a Result of Employee Warrant ExerciseGenmab A/S announced a capital increase of 28,011 shares resulting from employee warrant exercises, raising approximately DKK 44.3 million. The new shares represent 0.04% of the company's share capital and will be listed on Nasdaq Copenhagen. The total nominal share capital after the increase is DKK 62,405,855.GlobeNewswire Inc. · Sep 8, 2026

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsightDelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.GlobeNewswire Inc. · Sep 3, 2026

to start trading

GM

GMABGenmab A/S ADS

GMAB

Pay with—

Available Balance0.00

Your PositionYou don't own any GMAB yet.

Related Tickers

Earnings